Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 4Withdrawn 1Unknown 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Stomach Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Neutropenia 1Neoplasm Metastasis 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Esophageal Squamous Cell Carcinoma 1EFS 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Breast Neoplasms 1Anal Cancer Metastatic 1Advanced Solid Tumors 1Advanced Colorectal Cancer 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Oxaliplatin 14Cetuximab 11Leucovorin 9Fluorouracil 9Magnetic Resonance Spectroscopy 8Nivolumab 7pembrolizumab 6Capecitabine 6encorafenib 5Irinotecan 5Bevacizumab 5dehydroftorafur 4Specimen Handling 4adagrasib 3Immunoglobulin G 3Disulfides 3Biopsy 3selpercatinib 2durvalumab 2cemiplimab 2X-Rays 2Watchful Waiting 2Standard of Care 2Radiotherapy 2Panitumumab 2Observation 2Ipilimumab 2Injections 2Gemcitabine 2Folfox protocol 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Colonic Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT04294264 2024-11-18

TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer

Rutgers, The State University of New Jersey

Phase 2 Active not recruiting
50 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡